Smoking is associated with an elevated risk of advanced age-related macular degeneration, according to a study published in JAMA Ophthalmology.
Valerie Kuan, Ph.D., from University College London, and colleagues assessed whether smoking, alcohol consumption, blood pressure, body mass index, and glycemic traits are associated with increased risk of advanced AMD. Analysis included data from 16,144 individuals with AMD and 17,832 controls.
The researchers found that a one-standard deviation (SD) increase in logodds of genetically predicted smoking initiation was associated with higher risk of advanced AMD (odds ratio, 1.26), while a one-SD increase in logodds of genetically predicted smoking cessation was associated with lower risk of advanced AMD (odds ratio, 0.66). Similarly, genetically predicted increased lifetime smoking was associated with increased risk of advanced AMD (odds ratio, 1.32). There was an association seen between genetically predicted alcohol consumption and higher risk of geographic atrophy (odds ratio, 2.70). There was insufficient evidence to associate genetically predicted blood pressure, body mass index, and glycemic traits with advanced AMD.
Get the full story at pulmonologyadvisor.com
smoking macular degeneration
Go To Source For Respiratory Therapy Coverage
RT delivers in-depth coverage of the clinical, regulatory, and technology landscape for respiratory therapy—and reaches more than 28,000 key decision-makers and influencers. As one of healthcare’s most important data companies, we facilitate the rapid adoption of medical devices and practice management tools into the industry.
Go To Source For Respiratory Therapy Coverage RT delivers in-depth coverage of the clinical, regulatory, and technology landscape for respiratory therapy—and reaches more than 28,000 key decision-makers and influencers. As one of healthcare’s most important data companies, we facilitate the rapid adoption of medical devices and practice management tools into the industry. Go To Source For Respiratory Therapy Coverage RT delivers in-depth coverage of the clinical, regulatory, and technology landscape for respiratory therapy—and reaches more than 28,000 key decision-makers and influencers. As one of healthcare’s most important data companies, we facilitate the rapid adoption of medical devices and practice management tools into the industry. Go To Source For Respiratory Therapy Coverage RT delivers in-depth coverage of the clinical, regulatory, and technology landscape for respiratory therapy—and reaches more than 28,000 key decision-makers and influencers. As one of healthcare’s most important data companies, we facilitate the rapid adoption of medical devices and practice management tools into the industry.
